Full Press Release Details
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis.
ARGX
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
Key Takeaway: argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis